8-K: Cosmos Health Inc. Holds Annual Meeting, Approves Preferred Stock

Cosmos Health Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and the approval of Series B Preferred Stock.

Summary

• Cosmos Health Inc. held its 2026 Annual Meeting of Stockholders on July 15, 2026.
• Approximately 47% of the total outstanding shares were represented at the meeting.
• All proposals presented to the stockholders were passed.
• Six directors were elected to serve until the next annual meeting.
• The appointment of the independent registered public accounting firm was ratified.
• The 2026 Equity Omnibus Plan was approved.
• The designation and issuance of 100,000 shares of Series B Preferred Stock was approved.
• A Certificate of Designation for the Series B Preferred Stock will be filed with the Secretary of State of Nevada.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting on routine annual meeting outcomes and the designation of a new preferred stock class without significant financial performance updates or immediate strategic shifts.

Positives

• All submitted proposals, including the election of directors and the approval of the Series B Preferred Stock, were passed by stockholders.
• The company successfully ratified the appointment of its independent registered public accounting firm.
• The 2026 Equity Omnibus Plan was approved, indicating a commitment to employee incentives.
• A significant portion of the authorized but unissued preferred stock (294,000,000 shares) remains available for future designation and issuance.

Negatives

• Only approximately 47% of the total outstanding shares were present at the Annual Meeting, indicating potentially lower than desired shareholder engagement.
• A substantial number of votes were cast 'Withheld' for the election of directors, ranging from 4,467,745 to 5,926,554 votes.
• Significant opposition was noted for Proposal 2 (Ratification of Independent Auditors) with 4,391,554 votes against, and Proposal 3 (Equity Omnibus Plan) with 5,673,149 votes against, and Proposal 4 (Series B Preferred Stock) with 5,818,559 votes against.

Risks

• The Series B Preferred Stock has significant voting power (100,000,000 total votes, 1,000 votes per share) solely for the purpose of establishing a quorum, which could be used to influence meeting attendance requirements.
• Holders of Series B Preferred Stock are entitled to receive only par value ($0.001 per share) in the event of liquidation, which is a very low preference compared to common stock.
• The Series B Preferred Stock has no dividend rights, preemptive rights, redemption rights, or conversion rights, limiting its appeal to investors seeking income or capital appreciation through these mechanisms.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. The primary focus is on the outcomes of the annual meeting and the designation of Series B Preferred Stock.

Management Comments

• The Board believes it to be in the best interest of the Corporation and its shareholders to designate a new class of Series B Preferred Stock.
• The Company will file a certificate of designation with the Secretary of State of Nevada, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the shares of Series B Preferred Stock.

Industry Context

StockSavvy.ai notes that the designation of preferred stock, particularly with significant voting power for quorum purposes, is a common corporate governance tool used by companies, especially those incorporated in Nevada, to manage shareholder meetings and potential future capital structures. The approval of an equity omnibus plan also aligns with industry practices for incentivizing management and employees.

Comparison to Industry Standards

• The quorum requirement met by the Series B Preferred Stock's voting power is a mechanism sometimes employed by companies to ensure meetings can proceed, though a 47% turnout for a typical annual meeting can be considered average to below average depending on the company's size and investor base.
• The approval of an equity omnibus plan is standard practice across many industries, including technology and healthcare, to provide long-term incentives. Specific terms of such plans vary widely.
• The designation of preferred stock with limited rights (no dividends, no conversion, low liquidation preference) is often used for strategic purposes rather than as an investment vehicle for the holders themselves, differing from preferred stock designed for income generation.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The election of directors and approval of the equity plan and preferred stock designation directly affect shareholder rights and corporate governance. The Series B Preferred Stock's voting power for quorum could influence meeting proceedings.
• Employees: The approval of the 2026 Equity Omnibus Plan provides a framework for equity-based compensation, potentially benefiting employees and management.
• Management: Management will be subject to the oversight of the newly elected board and may benefit from the equity plan.

Next Steps

• The Company will file a certificate of designation with the Secretary of State of Nevada for the Series B Preferred Stock.
• The elected directors will serve until the next Annual Meeting and until their successors are duly elected and qualified.
• The 2026 Equity Omnibus Plan will be implemented.

Key Dates

Keywords

Cosmos Health Inc., Form 8-K, Annual Meeting, Series B Preferred Stock, Director Election, Equity Omnibus Plan, Nevada Corporation, SEC Filing